Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00074529

Enrollment

512

Registered

2003-12-16

Start date

2003-10-31

Completion date

2006-01-31

Last updated

2015-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Interventions

DRUGMK0677

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have probable Alzheimer's disease of mild or moderate severity. * A brain scan and laboratory results must be consistent with Alzheimer's disease. * The patient must be otherwise medically healthy.

Design outcomes

Primary

Measure	Time frame
Cognitive function over 12 month period; safety and tolerability	over 12 month period

Secondary

Measure	Time frame
AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.	over a 6 month and 12 month period

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026